谢英 博士, 副教授, 硕士生导师
药剂学系副主任
药剂党支部副书记、组织委员
Associate Prof. Ying Xie
Tel: (+8610) 82805351 (Office)
Email: bmuxieying@bjmu.edu.cn
谢英，1972年8月生于内蒙古。1996年毕业于北京师范大学化学系物理化学专业，获理学硕士学位。2005年获得北京大学药剂学博士学位。现任北京大学药学院药剂学系副教授，主要从事药学院长学制《物理化学》的教学，作为副主编及参编药学专业必修课教材及专著13部。
1993至1996年从事生物抗氧化过程酶催化机理的研究，参加两项国家自然科学基金资助项目；1996年以来从事药剂学研究，为多项新药制剂提供技术服务，负责北大方正创新药物研究基金1项，主持或作为共同申请人负责国家自然科学基金资助项目3项，作为主要研究人员参加国家重大科学研究计划（973）《纳米技术改善难溶性药物功效的应用基础》和重大新药创制:新制剂与新释药系统技术平台的研究工作。发表论文30余篇，申请/授权专利10/4项。近年来获得的奖励主要包括北京大学医学部教学优秀奖（2005, 2009, 2012, 2016，2022），北京大学药学院优秀党员（2010），北京大学工会先进个人（2007, 2015），北京大学医学部优秀工会工作者（2010, 2014, 2017），教育部科技进步二等奖（2004），DOVE PRESS首届中文摘要视频大赛奖（2015年）等。担任《Journal of Chinese Pharmaceutical Sciences》、《International Journal of Pharmaceutics》、《J Microencapsulation》、《Colloid and Surface, B》、《北京大学学报医学版》等学术期刊的审稿人。
主要科研方向
新型药物递送系统与生物药剂学
主要研究内容
脑靶向给药系统的研究
微针透皮给药系统
代表论文
1. Chunjie Bao#, Jialun Duan#, Ying Xie#, Yixuan Liu, Peishan Li, Jianwei Li, Huihui Zhao, Haitao Guo, Yanchen Men, Yuxin Ren, Jiarui Xu, Guiling Wang, and Wanliang Lu*. A novel oncogenic enhancer of estrogen receptor-positive breast cancer. Molecular Therapy: Nucleic Acids . 2022, 29(9): 836-851. [IF 10.183]
2. Liu Rui#, Xie Ying#, Xu Jiarui, Luo Qian, Ren Yuxin, Chen Ming, Duan Jialun, Bao Chunjie, Liu Yixuan, Li Peishan, Li Jianwei, Wang Guiling, Lu Wanliang*. Engineered stem cell biomimetic liposomes carrying levamisole for macrophage immunity reconstruction in leukemia therapy, Chemical Engineering Journal, 2022,447, 137582 . [IF 16.744]
3. Xu Jiarui#, Xie Ying#, Li Jianwei, Liu Rui, Chen Ming, Ren Yuxin, Luo Qian, Duan Jialun, Bao Chunjie, Liu Yixuan, Li Peishan, Lu Wanliang*. Development of fullerene nanospherical miRNA and application in overcoming resistant breast cancer. Materials Today Chemistry 2022, 26, 101019 [IF 7.613]
4. Ming Chen#, Ying Xie#, Qian Luo, Jiarui Xu, Yuxin Ren, Rui Liu, Huihui Zhao, Yuling Chen, Hexuan Feng, Yafei Du, Jianwei Li, Guiling Wang, Wanliang Lu*, Switchable nanoparticles complexing cisplatin for circumventing glutathione depletion in breast cancer chemotherapy. Chinese Chemical Letters 2022 in press [IF 8.455]doi: https://doi.org/10.1016/j.cclet.2022.107744
5. Jialun Duan#, Chunjie Bao#, Ying Xie#, Haitao Guo, Yixuan Liu, Jianwei Li, Rui Liu, Peishan Li, Jing Bai, Yan Yan, Limin Mu, Xueqi Li, Guiling Wang, Wanliang Lu*, Targeted core-shell nanoparticles for precise CTCF gene insert in treatment of metastatic breast cancer, Bioactive Materials, 2021,7;11:1-14. [IF 16.874]
6. Li Xueqi#, Li Jianwei#, Xu Jiarui, Chen Kun, Zhang Zhan, Duan Jialun, Luo Qian, Du Yafei, Chen Songyue, Xie Ying*, Lu Wanliang*. Nanostructure of Functional Larotaxel Liposomes Decorated with Guanine-Rich Quadruplex Nucleotide-Lipid Derivative for Treatment of Resistant Breast Cancer. Small . 2021 Jan 31:e2007391. doi: 10.1002/smll.202007391. [IF 15.153]
7. Yan Baiyi#, Liu Bailu#, Yi Lingyu#, Wang GuiLing, Xue Baizhong, Xie Ying*. Doxorubicin-loaded in situ gel combined with biocompatible hydroxyethyl cellulose hemostatic gauze for controlled release of drugs and prevention of breast cancer recurrence post-surgery. ACS Biomater. Sci. Eng. 2020, 6(10): 5959–5968. [IF 4.152]
8. Liu Chang#, Liu Xiaona#, Wang Guiling, Hei Yu, Meng Shuai, Yang Lingfei, Yuan Lan*, Xie Ying*, A dual-mediated liposomal drug delivery system targeting the brain: rational construction, integrity evaluation across the blood–brain barrier, and the transporting mechanism to glioma cells, Int J Nanomedicine . 2017,12: 2407-2425. [IF 5.008]
9. Yu Yu-Ping , Wang Qi , Liu Ying-Chun*, Xie Ying*，Molecular basis for the targeted binding of RGD-containing peptide to integrin aVb3，Biomaterials , 2014, 35(5):1667-1675.
10. Xie Ying, Ye Liya, Zhang Xiaobin，Cui Wei, Lou Jinning, Tauneji Nagai, Hou Xinpu*. Transport of nerve growth factor encapsulated into liposomes across the blood–brain barrier: In vitro and in vivo studies. J. Control. Release , 2005, 105(1-2):106-119.
